dr. ramalingam on the activity of osimertinib combinations in nsclc
Published 4 years ago • 125 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
1:08
dr. ramalingam on the os results of the flaura trial in egfr-mutant nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
6:06
osimertinib, the standard for egfr nsclc
-
1:31
dr. gold on the future of osimertinib in lung cancer
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
0:53
ramalingam compares third generation egfr tki osimertinib to older agents in nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
5:14
new standard for treating stage 4 egfr nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
1:38
dr. ramalingam on avelumab plus lorlatinib in nsclc